Sorrento Therapeutics
Presença
Sorrento Therapeutics é uma empresa listada sob o símbolo SRNE (US).
Executivos
Veja o organograma con seus 25 executivos principais
Biografias mais buscadas da Sorrento Therapeutics
Criar um alerta
para seguir os movimentos de executivos da Sorrento Therapeutics.
Farmacêutica
Sorrento Therapeutics possui 1.861 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Sorrento Therapeutics
- Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster | Sorrento Therapeutics
- Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19 | Sorrento Therapeutics
- Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc. | Sorrento Therapeutics
- News Releases | Sorrento Therapeutics
- Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors | Sorrento Therapeutics
- Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji | Sorrento Therapeutics
- Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US. | So
- Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes | Sorrento Therapeutics
- Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster | Sorrento Therapeutics
- Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans | Sorrento Therapeutics
- View more press releases Close
Redes sociais sobre Sorrento Therapeutics
- Sorrento Therapeutics na Wikipedia, Google News e Yahoo Finance
- Sorrento Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Henry Ji 
Ligue para a Sorrento Therapeutics em +1 858...
